Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Will Support Inflectra Launch With Dedicated Sales Force

Executive Summary

The company is on track to launch the first Remicade biosimilar in the US Nov. 21 using dedicated sales reps and resources from the innovative side of the business, though it will not be a traditional sales force.

Advertisement

Related Content

Pfizer v. J&J Sets Stage For Biosimilar Showdown Over Exclusive Contracts
Pfizer Sets The Stage For A Biosimilar Showdown Over Exclusive Contracts
Exclusive Remicade Contracts Are Slowing Biosimilar Uptake
Merck's Second-To-Market Renflexis Biosimilar Priced Below The First
Remicade: Biosimilars And Pricing Pressure Wear On J&J's Blockbuster Brand
Janssen Enriches Crohn's Portfolio In Deal For Protagonist's Oral IL-23 Inhibitor
J&J Forges Ahead In Immunology Despite Competitive Dynamics
Pfizer's Xeljanz: The Slow Road To Blockbuster Status
How Risky Is Pfizer’s Launch Of Its Remicade Biosimilar?
Pfizer Sets Inflectra Launch Date; J&J Plans To Fight Back

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097660

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel